What kind of BD opportunities is Puma interested in, specifically regarding stage (e.g., alisertib model) or earlier/later stage projects?

Alan Auerbach stated that Puma is looking at both commercial and development-stage assets. For commercial assets, they seek opportunities that fit into the existing organization and generate cash. For development-stage assets, they look for unique assets where they can add value clinically. They are not technology-agnostic and are open to assets outside of breast or lung cancer if they help cancer patients and benefit shareholders. “So from a BD perspective, we look at commercial assets, and we look at development stage ones. On the commercial side, I think that we've shown a strong ability to obviously cut costs, generate cash from a commercial asset. And if there's ones out there where we feel like we could fit it into the existing organization and continue to do that for shareholders, add on additional sales, build additional cash, I think that would be something very wise to do for the shareholders.”

PBYI

Puma Biotechnology (PBYI) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Puma Biotechnology Q2 FY26 — Strong NERLYNX Sales and Positive Net Income Guidance

Puma Biotechnology delivered a strong second quarter, driven by robust NERLYNX sales and increased demand, leading to an upward revision in full-year revenue and net income guidance. The company also achieved a significant financial milestone by becoming debt-free. While new prescriptions saw a slight decline, the focus remains on commercial execution and advancing the alisertib clinical pipeline, with plans to initiate Phase III trials in the future.

Highlights

Product revenue net increased to $53.6 million in Q2 FY26, up from $42 million in Q1 FY26 and $49.2 million in Q2 FY25.
NERLYNX ex-factory bottle sales were 2,929, representing an approximate 26% increase quarter-over-quarter and 12% increase year-over-year.
U.S. demand for NERLYNX was 2,986 bottles, an 8% increase quarter-over-quarter and 11% increase year-over-year.
The company is now debt-free after making the final $11.1 million principal loan payment related to its obligation with Athyrium.
Full-year 2026 net NERLYNX product revenue guidance was raised to $205 million to $209 million, up from prior guidance of $202 million to $206 million.

Concerns

New prescriptions for NERLYNX were down approximately 6% compared to Q1 FY26.
Full-year 2026 royalty revenue guidance was slightly lowered to $19 million to $22 million, from prior guidance of $20 million to $23 million, due to potential generic erosion in China.
The gross-to-net adjustment in Q2 FY26 was higher at 27.9% compared to 27% in Q1 FY26, driven by higher Medicaid share.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 net NERLYNX product revenue	$205 million to $209 million high materiality	FY26	High
Full-year 2026 gross to net adjustment	26.5% and 27.5% medium materiality	FY26	Medium
Full-year 2026 royalty revenue	$19 million to $22 million medium materiality	FY26	Medium
Full-year 2026 net income	$17 million to $20 million high materiality	FY26	High
Q3 2026 NERLYNX product revenue net	$54 million to $56 million medium materiality	Q3 · FY26	Medium
Q3 2026 royalty revenues	$2 million to $3 million medium materiality	Q3 · FY26	Medium
Q3 2026 gross to net adjustment	approximately 26% to 27% medium materiality	Q3 · FY26	Medium
Q3 2026 net income	$2 million and $2.5 million medium materiality	Q3 · FY26	Medium
Full-year 2026 SG&A expenses	increase by 1% to 2% medium materiality	FY26	Medium
Full-year 2026 R&D expenses	increase by 34% to 37% medium materiality	FY26	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
NERLYNX Product Revenue Net Strong growth in product revenue and bottle sales, driven by increased demand in the specialty distributor channel. Inventory decreased by $1 million. Product supply revenue to international partners: $23,000U.S. net sales of NERLYNX: $53.6 millionInventory decrease: $1 millionEx-factory bottle sales: 2,929Ex-factory bottle sales growth QoQ: 26%Ex-factory bottle sales growth YoY: 12%Inventory decrease (bottles): 57U.S. demand: 2,986 bottlesU.S. demand growth QoQ: 8%U.S. demand growth YoY: 11%Specialty pharmacy channel share: 61%Specialty distributor channel share: 39%Specialty distributor channel demand growth QoQ: 12%Specialty distributor channel demand growth YoY: 32%Call activity increase YoY: 18%Call activity increase QoQ: 2%Total prescriptions (TRx) increase QoQ: 7%Total prescriptions (TRx) increase YoY: 3%Enrollments growth QoQ: 1%Enrollments growth YoY: 12%Commercial new patient starts decline QoQ: 6%Commercial new patient starts growth YoY: 8%Patients starting NERLYNX at reduced dose: 73%	$53.6 million	8.9% increase	27.6% increase	—
Royalty Revenue Royalty revenue remained relatively stable quarter-over-quarter but declined year-over-year.	$2.9 million	-9.4% decrease	3.6% increase	—

Product announcements

Product	Type	Timeline	Details
NERLYNX	launch	Q1 2026

Deals & partnerships

International partners Sublicense agreement covering China for NERLYNX

The threshold for royalty rate reduction could be reached in late 2026 or 2027.

Risks & headwinds

Generic competition in China for NERLYNX Late 2026 or 2027

Potential royalty rate reduction

Mitigation:Not explicitly stated, but implies monitoring and managing expectations.

Higher gross to net adjustment Q2 2026

27.9% in Q2 2026 vs 27% in Q1 2026

Mitigation:Driven by higher Medicaid share, no specific mitigation stated.

New prescriptions decline Q2 2026

Down approximately 6% compared to Q1 2026

Mitigation:Continued messaging, adoption of dose escalation, and patient education resources.

What to watch in Q3 FY26

Alisertib ALISCA-Breast1 enrollment

Q3 FY26

Current Protocol amended, enrollment paused in some groups.

Target Begin enrollment under amended protocol.

Why it matters

Indicates progress in the clinical development of alisertib, a key pipeline asset.

That amendment to the protocol has been submitted to the FDA and the EU authorities and is being submitted to the IRBs as well. We are hoping to begin enrollment under that amended protocol in Q3.

Find out whether PBYI delivers this. Inve re-checks your case every morning.

Q&A highlights

What is the R&D spend trajectory beyond Q3 FY26 into FY27, and can Puma fund Phase III trials for both alisertib indications?

Alan Auerbach confirmed that based on current projections, Puma can fund Phase III trials for both alisertib in ER-positive breast cancer and small cell lung cancer, likely staggering them. He emphasized that being debt-free and cash flow positive enables this investment, and the company is committed to maintaining positive net income.

“So in terms of the R&D in '27, '28, '29, we've gotten this question from investors before, which is, let's say you want to do the Phase III trials of both alisertib in ER-positive breast cancer and in small cell lung cancer. Can you do that? And the answer to that is according to our current projections, yes.”

asked by Marc Frahm · answered by Alan Auerbach

2 min read 6 chapters

Detailed narrative

NERLYNX Commercial Performance

Puma reported strong Q2 FY26 NERLYNX product revenue net of $53.6 million, an increase from $42 million in Q1 FY26 and $49.2 million in Q2 FY25. Ex-factory bottle sales reached 2,929, representing a 26% quarter-over-quarter and 12% year-over-year increase. U.S. demand grew 8% quarter-over-quarter and 11% year-over-year to 2,986 bottles, primarily driven by the specialty distributor channel which saw 32% year-over-year growth.

The company estimates inventory decreased by $1 million in Q2 FY26.

Alisertib Clinical Development Progress

The company is advancing two Phase II trials for its investigational drug alisertib: ALISCA-Breast1 (HER2-negative ER-positive breast cancer) and ALISCA-Lung1 (small cell lung cancer). The ALISCA-Breast1 protocol was amended to focus enrollment on 40mg and 50mg dose groups based on interim data suggesting potentially better activity in patients with specific biomarkers.

For ALISCA-Lung1, the dose was further increased to 70mg BID, with 92 patients currently enrolled. Interim data from ALISCA-Lung1, including longer-term follow-up, is expected in Q4 FY26.

Future Alisertib Trials and Funding Outlook

Puma plans to initiate a second alisertib trial in small cell lung cancer, ALISCA-Lung2, in Q3 FY26, which will combine alisertib with paclitaxel. Initial data for ALISCA-Lung2 is anticipated in 2027. Management expressed confidence in the company's ability to fund potential Phase III trials for both alisertib indications in 2027, noting that they may stagger the trials if necessary to maintain positive net income, leveraging their newly debt-free status.

Financial Strength and Capital Allocation

Puma achieved a significant financial milestone by becoming debt-free in Q2 FY26, having made its final $11.1 million principal loan payment to Athyrium. The company reported $93.9 million in cash, cash equivalents, and marketable securities as of June 30, 2026.

Management reiterated its commitment to maintaining positive net income and is actively evaluating in-licensing or acquiring commercial or development-stage drugs to diversify its portfolio and leverage existing infrastructure.

Marketing and Sales Strategy

Marketing initiatives are focused on increasing awareness of NERLYNX's dual indication in HER2-positive breast cancer (early and metastatic settings) and addressing unmet needs. The sales team prioritizes patients at higher risk of recurrence, clinical education, and patient resources to support persistence and compliance. Dose escalation remains an important commercial priority, with 73% of patients starting NERLYNX at a reduced dose.

Royalty Revenue and Generic Risk

Full-year royalty revenue guidance was slightly lowered due to the potential for generic versions of NERLYNX reaching a specific market share threshold in China in late 2026 or 2027. This threshold, if met, would trigger a reduction in the royalty rate payable to Puma under its sublicense agreement covering China.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.